---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-030113"
form_type: "8-K"
ticker: "PPCB"
cik: "0001517681"
company_name: "Propanc Biopharma, Inc."
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T18:05:09.037205+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Propanc Biopharma enters amended employment agreement with CEO James Nathanielsz

## Summary
- New base salary of $600,000 AUD per annum, plus salary sacrifice for tuition up to $200,000 AUD.
- Annual discretionary bonus reduced to up to 100% of base salary (from 200% previously).
- Term of 3 years from July 1, 2022, with automatic yearly renewal unless terminated.
- Severance: one year's base salary upon termination without cause or company non-renewal; only accrued amounts if executive non-renewal.
- Includes one-year non-compete and indemnification provisions.

## SEC filing metadata
- accession: 0001493152-22-030113
- form_type: 8-K
- ticker: PPCB
- cik: 0001517681
- company_name: Propanc Biopharma, Inc.
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517681/000149315222030113/0001493152-22-030113-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517681/000149315222030113/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-030113
- JSON: https://secwatch.observer/filing/0001493152-22-030113.json
- Plain text: https://secwatch.observer/filing/0001493152-22-030113.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.